Highlights Nanexa AB

Equities

NANEXA

SE0007074166

Delayed Nasdaq Stockholm Other stock markets 04:30:26 2024-05-29 am EDT			5-day change	1st Jan Change
1.07 ^SEK	-2.73%		+25.59%	-13.01%

May. 15	Nanexa AB Elects Hanna Tilus as Members of the Board	CI
May. 15	Nanexa AB Receives Approval for NEX-22 Clinical Study	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Nanexa AB Receives Approval for NEX-22 Clinical Study	May. 15	CI
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 03	CI
Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	Apr. 16	CI
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	Dec. 20	CI
Nanexa Signs Feasibility Study Contract for PharmaShell; Shares Jump	Nov. 29	MT
Nanexa AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Nanexa AB Completes Clinical Phase I Study with NEX-20	23-10-05	CI
Nanexa AB Receives Patent in India	23-08-30	CI
Nanexa AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22	23-08-22	CI
Nanexa AB Obtains Pharmacokinetic Data from the NEX-20 Phase 1 Study Confirming Controlled Release of Lenalidomide	23-08-22	CI
Nanexa AB Completes Planned Recruitment to the Phase 1 Study of NEX-20	23-06-09	CI
Nanexa AB Signs Contract with Leading International Diabetes Cro for Phase I Study with Nex-22	23-06-01	CI
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Nanexa AB Announces Positive Outcome in the First Preclinical Study with NEX-22	23-03-23	CI
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-16	CI
Nanexa Starts the Phase 1 Study of NEX-20 According to Plan	22-12-06	CI
Nanexa, VitriVax Settle Patent Infringement Case Over Drug Delivery System	22-11-16	MT
Nanexa Receives Approval to Start Clinical Trial with NEX-20	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nanexa AB

Equities

NANEXA

SE0007074166

Highlights

Filters